Belsomra

PreclinicalSmall molecule

NNational Institute on Drug Abuse (NIDA)

Belsomra is one of 46 small molecule programs targeting Nicotine Dependence. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nicotine DependenceRecruiting

Nicotine DependencePreclinical

Recruiting

Competition

Competitive Landscape

45 competitors in Nicotine Dependence

#DrugCompanyPhaseTrials

Nicorette

Pfizer

Approved

5 2

Ritalin

Novartis

Approved

1 3

Revia

Teva

Approved

1 4

Lopid

Minipress

Niacor

Aricept

Epidiolex

Bayer Aspirin

Rozerem

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

Nicotine Dependence

NCT05630781

Clinical

Trials by Indication[1]

Nicotine Dependence1 trial

Orexin's Role in The Neurobiology of Substance Use Disorder

Recruiting·NNational Institute on Drug Abuse (NIDA)·Preclinical·NCT05630781·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Belsomra. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Belsomra compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Belsomra. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute on Drug Abuse (NIDA) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNational Institute on Drug Abuse (NIDA)

Belsomra

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Nicotine Dependence1 trial

References

Drug Info

Quick Facts

Related News